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a b s t r a c t
To explore the efﬁcacy of paraoxonase 1 (PON1) as a catalytic bioscavenger, we evaluated human
recombinant PON1 (rePON1) expressed in Trichoplusia ni larvae against sarin and soman toxicity using
microinstillation inhalation exposure in guinea pigs. Animals were pretreated intravenously with catalytically active rePON1, followed by exposure to 1.2 X LCt50 sarin or soman. Administration of 5 units
of rePON1 showed mild increase in the blood activity of the enzyme after 30 min, but protected the
animals with a signiﬁcant increase in survival rate along with minimal signs of nerve agent toxicity.
Recombinant PON1 pretreated animals exposed to sarin or soman prevented the reduction of blood O2
saturation and pulse rate observed after nerve agent exposure. In addition, rePON1 pretreated animals
showed signiﬁcantly higher blood PON1, acetylcholinesterase (AChE), and butyrylcholinesterase activity
after nerve agent exposure compared to the respective controls without treatments. AChE activity in
different brain regions of rePON1 pretreated animals exposed to sarin or soman were also signiﬁcantly
higher than respective controls. The remaining activity of blood PON1, cholinesterases and brain AChE
in PON1 pretreated animals after nerve agent exposure correlated with the survival rate. In summary,
these data suggest that human rePON1 protects against sarin and soman exposure in guinea pigs.
© 2011 Elsevier Ireland Ltd. All rights reserved.

1. Introduction
Human serum paraoxonase 1 (PON1, EC 3.1.8.1) is a polymorphic enzyme that is expressed mainly in the liver, secreted to blood,
and associated with high density lipoproteins (HDL) (Costa et al.,
2003; Humbert et al., 1993; Primo-Parmo et al., 1996). PON1 associated with HDL is a 45 kDa arylesterase which has been reported to
protect low density lipoproteins from oxidative modiﬁcations and
thus exerts the anti-atherogenic property of PON1 in atherosclerosis and cardiovascular diseases (Costa et al., 2005a; Harel et al.,

Abbreviations:
PON1, paraoxonase 1; HDL, high density lipoprotein;
rePON1, recombinant PON1; OP, organophosphate; CWNA, chemical warfare
nerve agent; AChE, acetylcholinesterase; BChE, butyrylcholinesterase; p-NPA,
p-nitrophenylacetate; BCA, bicinchoninic acid; Sarin, 2-(ﬂuoro-methylphosphoryl)oxypropane; Soman, 2-(ﬂuoromethylphosphoryl)oxy-3,3-dimethylbutane.
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of the authors and are not to be construed as ofﬁcial or as reﬂecting the views of the
Army, the Navy, or the Department of Defense, USA.
∗ Corresponding author at: 503 Robert Grant Avenue, Walter Reed Army Institute
of Research, Silver Spring, MD 20910. Tel.: +1 301 319 9548; fax: +1 301 319 9404.
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madhusoodana.nambiar@amedd.army.mil (M.P. Nambiar).
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2004; Josse and Masson, 2001; Mackness et al., 2002). PON1 has also
been described as a potential catalytic bioscavenger by a number
of groups due to its capacity to hydrolyze organophosphates (OPs)
and chemical warfare nerve agents (CWNAs) (Costa et al., 2005b;
Furlong et al., 2005; Otto et al., 2009; Otto et al., 2010; Stevens et al.,
2008). It can hydrolyze large amounts of OPs and CWNAs compared
to the stoichiometric bioscavenger human butyrylcholinesterase
(BChE), which acts in a 1:1 ratio, and would thus require smaller
doses and would reduce the cost of treatment (Doctor et al., 1991;
Doctor and Saxena, 2005; Lenz et al., 2005; Lenz et al., 2007; Rochu
et al., 2007).
The mechanism of action of OPs and CWNAs has been well
described as the irreversible inhibition of acetylcholinesterase
(AChE) in the central and peripheral nervous system leading to
abnormal accumulation of acetylcholine resulting in overstimulation of cholinergic transmission (Aldridge and Davison, 1953;
Bajgar, 2004; Flynn and Wecker, 1986). An effective countermeasure strategy for OP and CWNA toxicity has been centered on the
development of catalytic bioscavenger enzymes as pretreatments
which can rapidly hydrolyze large amounts of OPs and CWNAs
in the blood before they reach their targets. Recent research and
development identiﬁed human PON1 as a suitable candidate catalytic bioscavenger against OP and CWNA mediated toxicity (Costa
This article is a U.S. government work, and is not subject to copyright in the United States.
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et al., 2005b; Furlong et al., 2005; Li et al., 1995; Otto et al., 2009;
Otto et al., 2010; Rochu et al., 2007; Stevens et al., 2008). Most of
these studies were either performed under in vitro conditions, or in
rodent models of OP toxicity (Duysen et al., 2010; Fu et al., 2005; Li
et al., 1995; Wang et al., 2010). We also reported efﬁcient hydrolysis of the CWNA tabun in comparison to sarin and soman by PON1
using in vitro analysis (Valiyaveettil et al., 2010). Efﬁcacy of PON1
against CWNA toxicity in animal models needs to be investigated.
Recently, we have reported the protective efﬁcacy of human and
rabbit serum puriﬁed PON1 against sarin and soman inhalation toxicity in guinea pigs using microinstillation technology (Valiyaveettil
et al., 2011). Although serum puriﬁed enzymes can be used for
treatment, recombinant enzymes are preferred for the ease of
large scale production and elimination of polymorphism and heterogeneity. Pooling of serum from multiple donors may lead to
puriﬁcation of multiple PON1 mutants including one which has
lower catalytic activity. Another major concern with the use of
human derived protein therapeutics is the inherent potential for
infectious agents like hepatitis and human immunodeﬁciency virus
(Grillberger et al., 2009). Nevertheless, recombinant enzymes may
have difference in stability, pharmacokinetics and efﬁcacy, which
need to be investigated. Signiﬁcant hydrolysis of sarin and soman
by human recombinant PON1 (rePON1) expressed in Trichoplusia
ni larvae by in vitro analysis prompted us to further investigate
the protective efﬁcacy against CWNA toxicity (Valiyaveettil et al.,
2010). In this paper, we evaluated the efﬁcacy of human rePON1
against sarin and soman toxicity in guinea pigs using microinstillation inhalation exposure technology (Nambiar et al., 2007; Nambiar
et al., 2006).
2. Materials and methods
2.1. Materials
P-nitrophenylacetate (p-NPA), phenylacetate, acetylthiocholine, butyrylthiocholine, tetra monoisopropyl pyrophosphortetramide, huperzine A, 5,5 -dithiobis
(2-nitrobenzoic acid), and 4,4 -dipyridyl disulﬁde, 4,4 -dithiodipyridine were
purchased from Sigma (St. Louis, MO). Tissue protein extraction reagent and bicinchoninic acid (BCA) protein assay kit were purchased from Pierce (Rockford, IL).
CWNAs, sarin (99.8% pure) and soman (99.6% pure) were obtained from Edgewood
Chemical and Biological Center and used at US Army Medical Research Institute of
Chemical Defense (USAMRICD), Aberdeen Proving Ground, MD.

(Nambiar et al., 2007; Nambiar et al., 2006). Brieﬂy, the animals were anesthetized
(telazol, 40 mg/kg, i.m. and medetomidine, 0.125 mg/kg, s.c.) and saline or rePON1
(5 units) were administered through saphenous vein using a 28.5 gauge needle. Ear
blood was collected from animals before and after the administration of rePON1.
Animals were intubated and a microcatheter was inserted and placed 2 cm above
the bifurcation of the trachea for aerosolization of the CWNA. Thirty minutes
after administration of rePON1, the animals were exposed to sarin (846 mg/m3 )
or soman (841 mg/m3 ) using the microinstillation equipment (Trudell Medical,
Ontario, Canada) with a pulse rate of 40 pulses/min for 2–4 min (Che et al., 2008;
Perkins et al., 2010). Blood and tissue samples were collected from terminally
ill animals. The surviving animals were allowed to recover for 24 h, euthanized
by exsanguination and blood and tissues were collected for biochemical analysis.
2.5. Pulse rate and blood O2 saturation measurement
The blood O2 saturation (measured as % saturation of peripheral oxygen, SpO2 )
and pulse rate (measured as beats per min, bpm) of the animals were recorded
by using a pulse oximeter (Nonin Medical Instruments, Minneapolis, MN). The data
were recorded at pre-intubation, post-intubation and 30 s intervals during and after
exposure to CWNA for 15 min. Mean ± SEM values were plotted against time using
GraphPad Prism software.
2.6. Analysis of blood and brain enzyme activity
Blood samples collected at various time points were diluted with de-ionized
water. Brain tissue was dissected into different regions (frontal cortex, hind cortex, mid brain, cerebellum and hippocampus) and homogenized with 1:7 (wt/vol)
tissue protein extraction reagent. The activity of PON1, AChE and BChE in the
blood and AChE in the brain was determined as described earlier (Ellman et al.,
1961; Valiyaveettil et al., 2011). Protein content in the brain samples was estimated by BCA protein assay kit. The activity of various enzymes in the blood
and brain was expressed as mol/min/ml or mol/min/mg protein, respectively.
2.7. Data analysis
The animal survival data was plotted using Kaplan–Meier method and
analyzed by Logrank test. The pulse rate and blood O2 saturation data at multiple time points were analyzed by two-way ANOVA with Bonferroni post-test.
Blood and brain enzyme activity data were analyzed by using Mann–Whitney
test.

3. Results
3.1. Recombinant human PON1 protects against sarin and soman
toxicity

2.2. Animals
All animal procedures were performed at USAMRICD in compliance with the
Animal Welfare Act and other federal statutes and regulations relating to animals
and experiments involving animals and adhered to principles stated in the Guide
for the Care and Use of Laboratory Animals (NRC Publication 1996 edition) with
an approved Institutional Animal Care and Use Committee protocol. Male Hartley
guinea pigs (250–300 g, Charles River Laboratories, Wilmington, MA) were used for
the studies.
2.3. Expression and puriﬁcation of recombinant human PON1
Recombinant PON1 was expressed in T. ni larvae and was puriﬁed as described
earlier in collaboration with Chesapeake PERL (Savage, MD) (Otto et al., 2010;
Valiyaveettil et al., 2010). Brieﬂy, baculovirus expression vector containing human
PON1 cDNA (encoding wild type human PON1 with Q192 polymorphism) was orally
infected to larvae followed by incubation at controlled conditions for 96 h. The
harvested larvae were stored under frozen conditions until the recovery of PON1
enzyme. The extraction and puriﬁcation of rePON1 was performed by using multiple chromatography procedures as described earlier (Otto et al., 2010; Valiyaveettil
et al., 2010). The purity of rePON1 was analyzed by SDS–PAGE and Western blotting. The catalytic activity of puriﬁed rePON1 (>99% pure) was analyzed using
p-NPA substrate and expressed as units/mg protein or units/ml (Valiyaveettil
et al., 2010). Enzyme activity was calculated with the molar extinction coefﬁcient
(18 mM−1 cm−1 ) of p-nitrophenol. The puriﬁed rePON1 showed a speciﬁc activity of
8.5 units/mg protein.
2.4. Sarin and soman microinstillation inhalation exposure
Control and rePON1 pretreated guinea pigs were exposed to sarin and soman
using the microinstillation inhalation exposure methodology as described earlier

The survival data of guinea pigs pretreated with 5 units of
rePON1 (∼600 g of protein) followed by exposure to 846 mg/m3 of
sarin or 841 mg/m3 of soman are shown in the Kaplan–Meier curve
(Fig. 1). Most of the control animals exposed to sarin or soman without any treatment died within 10–15 min, while majority of rePON1
pretreated animals exposed to sarin or soman survived for 24 h. The
non-surviving animals in rePON1 pretreated group died 2–4 h after
CWNA exposure. Guinea pigs pretreated with 5 units of rePON1 and
then exposed to 846 mg/m3 sarin showed ∼80% survival rate that
is signiﬁcantly higher than that seen in control animals exposed
to sarin (p = 0.009). In animals exposed to 841 mg/m3 of soman,
rePON1 pretreatment showed a ∼71% survival rate that was significant compared to untreated controls (p = 0.015). The animals that
survived for 24 h in both sarin and soman groups were healthy and
active.
3.2. Recovery of pulse rate and blood O2 saturation in rePON1
pretreated guinea pigs exposed to CWNAs
Guinea pigs exposed to sarin (846 mg/m3 ) showed a gradual
drop in the heart rate during the entire 15 min of recording until
the death of the animal, as reported previously (Valiyaveettil et al.,
2011) (Fig. 2A). Recombinant PON1 pretreated animals exposed
to sarin showed a similar decrease in the pulse rate up to 5 min,
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Fig. 1. Kaplan–Meier survival curve of guinea pigs pretreated with rePON1 and
exposed to sarin and soman. Male Hartley guinea pigs were intravenously administered with saline or human recombinant PON1 (5 units) and 30 min later exposed
to 846 mg/m3 of sarin or 841 mg/m3 of soman using microinstillation method as
described in “Section 2”. The surviving animals were allowed to recover for 24 h.
The percentage of survival of guinea pigs was plotted against time in GraphPad
Prism using Kaplan–Meier survival curve and the statistical signiﬁcance was analyzed by Logrank test. n = 14 for saline controls exposed to sarin; n = 10 for saline
controls exposed to soman; n = 5 for human recombinant PON1 (rePON1) exposed
to sarin, n = 7 for rePON1 exposed to soman.

which returned back to baseline by 8 min (Fig. 2A). The pulse rate
in rePON1 pretreated animals exposed to sarin showed a statistically signiﬁcant increase 10 min after the start of sarin exposure
compared to the respective sarin controls (Fig. 2A). In the case

3

of soman (841 mg/m3 ), the control guinea pigs showed a sharp
drop in pulse rate for the ﬁrst 5 min. Pulse rate tend to return
back, but remained below baseline levels up to 10 min and then
decreased further until the death of the animal (Fig. 2B). Pulse
rates in animals pretreated with rePON1 and exposed to soman
showed a relatively lesser decrease and were quickly returned and
maintained at baseline levels and that was statistically signiﬁcant
compared to untreated soman controls from 10 min after exposure
(Fig. 2B).
The blood O2 saturation curve of sarin exposed animals showed
a decrease till the end of 15 min, although there was a drift
toward normal levels at 7.5 min (Fig. 2C). Recombinant PON1 pretreated animals exposed to sarin showed a drop in the blood
O2 saturation that peaked around 6 min and then returned back
to baseline at 10 min and maintained until 15 min of recording. The blood O2 saturation at 10, 11, 14 and 15 min after
sarin exposure in rePON1 pretreated animals was signiﬁcantly
higher than the respective sarin controls (Fig. 2C). In soman
exposed animals, the blood O2 saturation curve showed a pattern resembling pulse rate with a decrease at 4–5 min and a
trend of returning back to baseline at 8–9 min (Fig. 2D). Recombinant PON1 pretreated animals exposed to soman also showed
a pattern similar to pulse rate that returned back to baseline
at 8 min and that was signiﬁcantly higher than the respective
soman controls at 11 and 15 min (Fig. 2D). The restoration of blood
O2 saturation and pulse rate in rePON1 pretreated guinea pigs
exposed to sarin or soman correlated with the increase in survival
rate.

Fig. 2. Pulse rate and blood O2 saturation curves of animals exposed to sarin and soman. Guinea pigs were administered with saline or rePON1 and exposed to sarin (A
and C) or soman (B and D) as described in Fig. 1 and “Section 2”. The pulse rate (A and B) in beats per min (bpm) and blood O2 saturation (C and D) were recorded using a
pulse oximeter every 30 s for 15 min and mean ± SEM values were plotted against time (min). The data was analyzed by using two-way ANOVA with Bonferroni post-test.
Saline controls exposed to sarin or soman, n = 8; human recombinant PON1 (rePON1) exposed to sarin, n = 4; and rePON1 exposed to soman, n = 5 ((*) 0.05 < p < 0.01; (**)
0.01 < p < 0.001; (***) p < 0.001).
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Fig. 3. Blood activity of PON1, AChE and BChE in guinea pigs exposed to sarin and soman. As described in Fig. 1, the animals were pretreated with rePON1 followed by
exposure to sarin (A–C) or soman (D–F). The activity of PON1 (A and D), AChE (B and E), and BChE (C and F) in the pre- and post-exposed blood samples were analyzed as
described in “Section 2”. The results were expressed as mol/min/ml of blood (n = 6 for control, and 4–5 for rePON1; (*) 0.05 < p < 0.01; (**) 0.01 < p < 0.001).

3.3. Activity of PON1, AChE and BChE in the blood of guinea pigs
treated with rePON1and exposed to sarin and soman
As reported earlier, the activity of PON1, AChE and BChE in
the blood of guinea pigs exposed to sarin (846 mg/m3 ) or soman
(841 mg/m3 ) showed a signiﬁcant reduction compared to the
respective controls (Valiyaveettil et al., 2011) (Fig. 3). Administration of rePON1 showed a marginal insigniﬁcant increase in the
activity of PON1 and AChE in the blood of guinea pigs (Figs. 3A,
B, D, and E), while blood BChE activity was unaltered (Figs. 3C
and F). Recombinant PON1 pretreated animals exposed to sarin or
soman also showed signiﬁcant decreases in blood PON1, AChE and
BChE activities, but this decrease was considerably lower than that
of respective nerve agent exposed controls (Fig. 3). The residual
blood PON1, AChE and BChE activities in rePON1 pretreated animals
exposed to sarin or soman correlated with the increased survival
rate after CWNA exposure.
3.4. Brain AChE activity in rePON1 pretreated sarin and soman
exposed guinea pigs
Guinea pigs exposed to sarin or soman showed a signiﬁcant
reduction in the activity of AChE in different regions of the brain as
observed earlier (Valiyaveettil et al., 2011) (Fig. 4). AChE activity in
most of the brain regions of rePON1 pretreated animals exposed
to sarin was signiﬁcantly higher than that of nerve agent controls (Figs. 4A–E). The frontal cortex of PON1 pretreated animals
exposed to sarin showed AChE activity similar to that of unexposed controls (Fig. 4A). In the case of soman, all the brain regions
of rePON1 pretreated animals showed signiﬁcantly higher AChE
activity compared to nerve agent controls (Figs. 4A–E). Recombinant PON1 pretreated animals exposed to sarin or soman retained
∼40–70% of AChE activity, possibly contributing to the survival of
animals after CWNA exposure.

4. Discussion
Taken together, the results described here demonstrate that
human rePON1 produced in T. ni larvae and administered intravenously to guinea pigs protected against sarin and soman
inhalation toxicities. These data support our previous observation
that puriﬁed human and rabbit serum PON1 protects against CWNA
toxicity (Valiyaveettil et al., 2011). The observed protective efﬁcacy
of rePON1 was reﬂected by the increase in survival rate, lack of
behavioral symptoms, restoration of pulse rate and blood O2 saturation, signiﬁcantly higher levels of blood bioscavenger enzymes
and blood and brain AChE levels in pretreated animals compared to
the respective nerve agent exposed controls, indicating that PON1
pretreatment decreases the overall toxicity of sarin and soman
in guinea pigs. Signiﬁcant protection was observed with 5 units
of rePON1, which is approximately 600 g of protein per animal
(∼2.5 mg/kg). Higher doses of rePON1, in the range of 10–20 units
(∼5–10 mg/kg), may be adequate to efﬁciently protect against 2–5
X LCt50 of nerve agent exposure, which has to be conﬁrmed by
performing more detailed experiments.
As we reported earlier with human and rabbit serum PON1, the
decrease in pulse rate and blood O2 saturation curves due to CWNA
exposure was returned to the baseline values in rePON1 pretreated
animals exposed to nerve agents, indicating that PON1 pretreatment leads to immediate restoration of normal respiration in the
surviving animals (Valiyaveettil et al., 2011). Animals pretreated
with rePON1 and then exposed to sarin showed a lower blood O2
saturation at 5–8 min compared to untreated animals exposed to
sarin. Although this drop in blood O2 saturation was not significant, such a drop was also observed in animals pretreated with
human serum puriﬁed PON1 previously (Valiyaveettil et al., 2011).
In contrast, such a drop in blood O2 saturation was not observed
with rabbit serum puriﬁed PON1 (Valiyaveettil et al., 2011). This
might be due to the higher catalytic efﬁciency of rabbit serum PON1
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Fig. 4. Brain AChE activity in sarin and soman exposed guinea pigs. The animals were pretreated with rePON1 and exposed to sarin or soman as described in Fig. 1, and
different regions of the brain were dissected and extracted with tissue protein extraction reagent. The activity of AChE in the brain extracts were analyzed as described in
“Section 2”. The results were expressed as mol/min/mg protein. Shown are the mean ± SEM values for AChE activity from frontal cortex (A), hind cortex (B), mid brain (C)
cerebellum (D), and hippocampus (E) (control unexposed, n = 6; sarin or soman exposed, n = 6; and rePON1, n = 4–5; (*) 0.05 < p < 0.01; (**) 0.01 < p < 0.001).

compared to recombinant or human serum PON1 against sarin and
soman as observed earlier (Valiyaveettil et al., 2010).
Administration of rePON1 showed mild increase in the activity
of PON1 in the blood of guinea pigs after 30 min. Upon nerve agent
exposure, the activities of PON1, BChE and AChE were signiﬁcantly
decreased in controls and rePON1 pretreated animals. However, the
rePON1 pretreated animals exposed to CWNA showed signiﬁcantly
higher activity of blood enzymes compared to the respective agent
exposed controls, indicating the in vivo hydrolysis of CWNAs by
rePON1. The increased enzyme activity in the blood of rePON1 pretreated animals exposed to CWNAs can further protect the guinea
pigs against repeated exposure of CWNAs. Similarly, AChE activity from different parts of the brain of rePON1 pretreated animals
exposed to nerve agents was higher compared to the respective
controls indicating that rePON1 pretreatment protects the central nervous system. The preservation of the activity of AChE and
bioscavenger enzymes in the brain and blood of PON1 pretreated
animals may be a key reason for the increased survival rate of animals.
As observed earlier with administration of puriﬁed serum PON1,
intravenous injection of rePON1 showed only a minimum increase
in the blood activity of the enzyme in guinea pigs after 30 min
(Valiyaveettil et al., 2011). This might be possibly due to the
rapid degradation/clearance of the exogenous PON1 in guinea pigs
(Boado et al., 2011). The rapid clearance of exogenous PON1 raises
the need for pharmacokinetic analysis of the rePON1 and the development of PON1 mutants with better pharmacokinetics (Boado
et al., 2011). Reduced half-life of PON1 in circulation can possibly be attributed to poor association of exogenously administered
PON1 with HDL, which is the natural in vivo carrier of the enzyme
(Gaidukov et al., 2009; Harel et al., 2004; Sorenson et al., 1999).
Modulators of PON1 which can increase the endogenous expression of the enzyme may overcome the drawback of reduced half-life
associated with exogenous PON1 (Costa et al., 2011; Costa et al.,
2005c). Natural association of endogenously induced PON1 with

HDL may increase the circulatory half-life of PON1. The marginal
increase in the activity of PON1 with exogenous administration of
recombinant or human and rabbit serum puriﬁed PON1 was sufﬁcient to protect against 1.2 X LCt50 of nerve agents (Valiyaveettil
et al., 2011). Dietary polyphenolic compounds such as quercetin
and resveratrol are reported to increase the endogenous expression
of PON1 by 2–3 fold which possibly could be adequate to protect
against lethal doses of CWNA exposure (Boesch-Saadatmandi et al.,
2010; Gouedard et al., 2004).
5. Conclusion
In conclusion, PON1 from multiple sources (recombinant and
human and rabbit serum puriﬁed) protected against 1.2 X LCt50
sarin and soman in guinea pigs using microinstillation inhalation
exposure (Valiyaveettil et al., 2011). The protective efﬁcacy was
observed in conjunction with mild increase in the blood levels
of the enzyme, possibly owing to rapid clearance of exogenous
PON1. Recombinant PON1 pretreated animals retain higher levels
of cholinesterase and PON1activities that might be responsible for
the increased protection and survival. Research efforts to generate
rePON1 with higher catalytic efﬁciency and enhanced pharmacokinetics can drive the future development of PON1 as catalytic
bioscavenger suitable to combat against CWNA exposure.
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